Jakubowski Christopher D, Vertosick Emily A, Untch Brian R, Sjoberg Daniel, Wei Elizabeth, Palmer Frank L, Patel Snehal G, Downey Robert J, Strong Vivian E, Russo Paul
Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
J Surg Oncol. 2016 Sep;114(3):375-9. doi: 10.1002/jso.24327. Epub 2016 Jun 23.
Patients with metastatic RCC can undergo metastasectomy to improve survival time. Our goal was to provide and compare characteristics and oncological outcomes of RCC patients who underwent complete metastasectomy at a single organ site.
A total of 138 RCC patients were identified as undergoing complete metastasectomy at a single organ site including adrenal, lung, liver, pancreas, or thyroid. Competing risk regression analysis was used to assess RFS and CSS adjusting for several covariates.
In this highly selected cohort, RFS and CSS was 27% and 84% at 5 years following metastasectomy, respectively. Univariate analysis revealed that removal of multiple tumors, younger age, and a shorter interval between nephrectomy and metastasis was associated with worse RFS. Larger tumors and sarcomatoid histology at nephrectomy was associated with worse CSS. We found no evidence that metastases at the time of RCC diagnosis influenced recurrence or survival. Tumor size, number of metastases resected, and time from nephrectomy to first recurrence was significantly different, but recurrence rates were not found to be significantly different, when compared across all organ sites.
These findings inform clinical and surgical management of select RCC patients with isolated metastasis to one of several organ sites. J. Surg. Oncol. 2016;114:375-379. © 2016 Wiley Periodicals, Inc.
转移性肾细胞癌(RCC)患者可接受转移灶切除术以延长生存时间。我们的目标是提供并比较在单一器官部位接受完全转移灶切除术的RCC患者的特征及肿瘤学结局。
共纳入138例在单一器官部位(包括肾上腺、肺、肝、胰腺或甲状腺)接受完全转移灶切除术的RCC患者。采用竞争风险回归分析评估无复发生存期(RFS)和总生存期(CSS),并对多个协变量进行校正。
在这个经过高度筛选的队列中,转移灶切除术后5年的RFS和CSS分别为27%和84%。单因素分析显示,切除多个肿瘤、年龄较轻以及肾切除术与转移之间的间隔时间较短与较差的RFS相关。肾切除时肿瘤较大和肉瘤样组织学类型与较差的CSS相关。我们没有发现证据表明RCC诊断时的转移会影响复发或生存。在所有器官部位进行比较时,肿瘤大小、切除的转移灶数量以及从肾切除到首次复发的时间有显著差异,但未发现复发率有显著差异。
这些发现为部分孤立转移至多个器官部位之一的RCC患者的临床和外科治疗提供了依据。《外科肿瘤学杂志》2016年;114:375 - 379。© 2016威利期刊公司。